CCL2 and sickle cell disease: Similarly, RVX treatment decreased MCP-1 plasma levels and MMP-9 protein levels in the external jugular vein of mice following catheter thrombosis [15], as well as IL-6 plasma level and neutrophil levels in a mouse model of sickle cell disease [64].